Stocks Health care RNTX
NASDAQ · Health careRein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. brought in $0 of revenue over the twelve months to June 30, 2026. It posted a net loss of $49.8M. At June 30, 2026 it held $8.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Rein Therapeutics, Inc.
- Net worth
- Rein Therapeutics, Inc. has a market value (market cap) of $49M at the latest share price, and shareholders' equity of $55.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $49.9M. Over the 12 months to June 30, 2026: revenue $0, net loss $49.8M.
- Cash flow
- In fiscal 2025 operations used $19.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Rein Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Rein Therapeutics, Inc. does
Rein Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RNTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$49.9M | -$1.96 | n/a |
| 2024 | $0 | -$62.9M | -$3.51 | n/a |
| 2023 | $0 | -$15.7M | -$3.42 | n/a |
| 2022 | $0 | -$27.3M | -$6.02 | n/a |
| 2021 | $0 | -$26.2M | -$5.89 | -$23.9M |
| 2020 | $0 | -$27.3M | -$12.39 | -$20.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Rein Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 4, 2026
- August 27, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- July 21, 2026
- July 14, 2026Passive stake changed SCHEDULE 13G/A
- June 8, 2026
- June 8, 2026Additional proxy material DEFA14A
Insider trades
What the people running Rein Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Von Rickenbach Josef HDirector | Bought | 4,500 | $4.8K |
| May 26, 2026 | Von Rickenbach Josef HDirector | Bought | 23,190 | $24.5K |
| May 22, 2026 | Von Rickenbach Josef HDirector | Bought | 15,950 | $16.7K |
| May 21, 2026 | Von Rickenbach Josef HDirector | Bought | 3,420 | $3.6K |
| April 30, 2026 | Windsor James BrianSee Remarks, Director | Bought | 25,000 | $25K |
| November 14, 2025 | Voss Capital, LP10% owner | Boughtindirect | 104,183 | $127.6K |
Who owns RNTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bios Capital Management, LP13G, passive with 23 related filers | 9.99% | May 8, 2026 |
| Funicular Funds, LP13G, passive with 2 related filers | 6.7% | May 7, 2026 |
| Voss Capital, LP13G, passive with 4 related filers | 6.6% | July 14, 2026 |
| ADAR1 Capital Management, LLC13G, passive with 1 related filers | 5.3% | August 14, 2026 |
| Lynwood Capital Management Inc.13G, passive with 2 related filers | 5% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 60 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Voss Capital, LP | 5,261,921 | +873,559 |
| Cable Car Capital, LP | 5,195,000 | +4,775,000 |
| ADAR1 Capital Management, LLC | 4,500,000 | new |
| Vanguard Capital Management LLC | 3,377,910 | +2,379,389 |
| BIOS Capital Management, LP | 2,982,375 | +1,000,000 |
| Ikarian Capital, LLC | 2,950,000 | new |
| Great Point Partners LLC | 2,575,000 | new |
| Citadel Advisors LLC | 2,438,711 | new |
| Velan Capital Investment Management LP | 1,700,000 | new |
| Senvest Management, LLC | 1,230,895 | +1,000,000 |
| Prosight Management, LP | 1,100,000 | +688,400 |
| Bleichroeder LP | 1,000,000 | new |
| Boothbay Fund Management, LLC | 889,450 | new |
| Geode Capital Management, LLC | 733,139 | +388,449 |
| University of Texas/texas AM Investment Management Co | 511,610 | 0 |
| Vanguard Fiduciary Trust Co | 382,515 | +228,003 |
| State Street Corp | 379,604 | +303,700 |
| Empery Asset Management, LP | 370,834 | new |
| Sigma Planning Corp | 353,677 | +5,000 |
| BlackRock, Inc. | 326,204 | +257,676 |
Insiders
3 insiders reported holding 1,016,001 shares in total, about $576.7K at the last price.
| Holder | Shares |
|---|---|
| Voss Capital, LP10% owner | 926,441926,441 held indirectly |
| Von Rickenbach Josef HDirector | 62,514 |
| Windsor James BrianSee Remarks, Director | 27,046 |
Questions about RNTX
What does Rein Therapeutics, Inc. do?
Rein Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as RNTX. Its shares trade on NASDAQ under the ticker RNTX.
What is Rein Therapeutics, Inc.'s net worth?
Rein Therapeutics, Inc. has a market value (market cap) of $49M at the latest share price, and shareholders' equity of $55.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Rein Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $49.8M.
How much revenue does Rein Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Rein Therapeutics, Inc. reported revenue of $0.
When did Rein Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 4, 2026.
When is Rein Therapeutics, Inc.'s next earnings report?
Rein Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RNTX with
Follow RNTX
Get an email when Rein Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Rein Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.